<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gater, Laura</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mandrup-Poulsen, Thomas</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">IL-1 Receptor Antagonist Therapy in Type 2 Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Impaired β-cell function and decreased β-cell mass due to apoptosis contribute to impaired insulin secretion in patients with type 2 diabetes. Interleukin-1 receptor antagonists (IL-1Ra) can block β-cell apoptosis, and patients with type 2 diabetes are known to have reduced levels of IL-1Ra expression. This article presents results from a recent study examining anakinra in the treatment of type 2 diabetes.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>